Investors

 

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.

Copyright Nasdaq. Minimum 15 minutes delayed.